CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
Cumberland Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $100.39M | $197.05M |
| Enterprise Value | $96.19M | $106.56M |
| PS Ratio | 3.21 | 3.93 |
| PB Ratio | 5.76 | 2.14 |
| P/TBV Ratio | 5.77 | 2.46 |
| P/FCF Ratio | 146.79 | 18.25 |
| P/OCF Ratio | 134.57 | 13.78 |
Enterprise value
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 3.08 | 2.69 |
| EV / FCF | 140.65 | 21.02 |
Income (trailing twelve months)
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $31.27M | $57.94M |
| Operating Income | -$9.63M | -$21.44M |
| Pretax Income | -$9.57M | -$14.45M |
| Net Income | -$10.92M | -$22.46M |
| EBITDA | -$5.49M | -$16.91M |
| EPS (Diluted) | -$0.73 | -$0.83 |
Margins
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -30.8% | -44.5% |
| Pretax Margin | -30.6% | -13.0% |
| Profit Margin | -34.9% | -39.2% |
| EBITDA Margin | -17.5% | -31.3% |
| FCF Margin | 2.19% | -8.85% |
Returns
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -48.1% | -53.1% |
| Return on Assets (ROA) | -16.7% | -41.0% |
| Return on Invested Capital (ROIC) | -59.7% | -32.0% |
| Return on Capital Employed (ROCE) | -34.8% | -37.8% |
Growth
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -1.10% | 6.01% |
| FCF Growth (YoY) | -90.3% | 2.34% |
| Revenue Growth (3Y CAGR) | 1.95% | 2.25% |
| Revenue Growth (5Y CAGR) | 3.52% | 6.42% |
Balance sheet
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.86M | $62.42M |
| Net Cash (Debt) | $3.86M | $15.68M |
| Net Cash Per Share | $0.26 | $0.65 |
| Equity (Book Value) | $17.44M | $48.79M |
| Book Value Per Share | $1.16 | $1.36 |
| Tangible Book Value | $17.39M | $23.06M |
| Working Capital | -$1.55M | $75.77M |
Financial position
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.96 | 3.30 |
| Quick Ratio | 0.49 | 2.39 |
| Interest Coverage | -31.13 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $745.97K | -$12.35M |
| Capital Expenditures | -$62.07K | -$1.06M |
| Free Cash Flow | $683.90K | -$20.28M |
| FCF Per Share | $0.05 | -$0.41 |
Efficiency
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.48 | 0.38 |
| Revenue Per Employee | $336.22K | $398.96K |
| Profits Per Employee | -$117.40K | -$732.08K |
| Employee Count | 93 | 73 |
Dividends and yields
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -10.9% | -21.2% |
| FCF Yield | 0.68% | -7.64% |
| Buyback Yield | 0.07% | -0.58% |
| Shareholder Yield | 0.07% | 0.00% |
Shares
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 14,983,100 | 59,128,900 |
| Shares Change (YoY) | 2.08% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 2,961,040 | 48,744,500 |
| Shares Held by Insiders | 80.2% | 11.8% |
| Shares Held by Institutions | 16.5% | 59.4% |
Taxes
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $36.66K | $91.50K |
Scores
| Measure | Cumberland Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 0.51 | 0.10 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | -2.64 | -2.62 |
Calculated by StockData from Cumberland Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.